Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 15Esophageal Neoplasms 12Colorectal Neoplasms 9Stomach Neoplasms 6Rectal Neoplasms 6Esophageal Squamous Cell Carcinoma 6Pancreatic Neoplasms 5Neoplasms 4Liver Neoplasms 4Cholangiocarcinoma 4Neoplasm Metastasis 3Melanoma 3Carcinoma, Renal Cell 3Liver Diseases 2Gastrointestinal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Adenocarcinoma 2Waldenstrom Macroglobulinemia 1Vulvar Neoplasms 1Vaginal Neoplasms 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Unresectable Hepatocellular Carcinoma 1Unresectable Biliary Tract Cancer 1Triple Negative Breast Neoplasms 1Tongue Neoplasms 1Thyroid Neoplasms 1

Interventions

Gemcitabine 6130-nm albumin-bound paclitaxel 4S 1 (combination) 2Radiosurgery 2Oxaliplatin 2Leucovorin 2Fluorouracil 2Electroporation 2zimberelimab 1surufatinib 1Tomography, X-Ray Computed 1Pancreatectomy 1Irinotecan 1Immunotherapy 1Heavy Ion Radiotherapy 1Endoscopy 1Drug Therapy 1Diagnostic Imaging 1Albumin-Bound Paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Locally Advanced Pancreatic Cancer × Immunotherapy × Gastrointestinal × Clear all
NCT06009029 2023-08-24

SBRT Combined With Zimberelimab (GLS-010) in Locally Advanced Pancreatic Cancer (SPARK-1 Study)

Peking University Third Hospital

Phase 2 Not yet recruiting
96 enrolled
Gastrointestinal

Locally Advanced Pancreatic Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡